New World-Leading Formulation for Human Levothyroxine Sodium Tablet Market
On 20 January 2015, the FDA approved the new advanced formula of Thyro-Tabs® (levothyroxine sodium tablets), USP (NDA # 21-116) for the human market. This approval represents the cumulation of continued research since the approval of the original formulation in October 2002 to further advance the reliability and stability of Thyro-Tabs®.
On 13 November 2015, LLOYD, Inc. received an additional approval letter from FDA for longer expiry dating for Thyro-Tabs® for the human market. This new world-leading formulation now has the longest product stability dating for most of the human levothyroxine sodium tablet strengths prescribed in the U.S.